Browsing by Author "Rosenbaum Fuentes, Andrés Ricardo"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Contacto clínico precoz: experiencia de diseño e implementación de un curso de servicio comunitario en medicina
    (2019) Rivera Mercado, Solange; Rosenbaum Fuentes, Andrés Ricardo; Rojas González, Pamela; Rioseco Castillo, Andrea; García-Huidobro Munita, Diego; Rojas Carvallo, Pedro Francisco
  • Thumbnail Image
    Item
    Improved vocal quality and decreased vocal effort after botulinum toxin treatment for laryngeal dystonia
    (Elsevier Ireland Ltd, 2024) Badia Venti, Pedro Ignacio; Holmberg Pavez, Jorge Ignacio; Lagos Villaseca, Antonia Elisa; Leung Caballero, Jai-sen Francisco; Napolitano Valenzuela, Carla Andrea; Rosenbaum Fuentes, Andrés Ricardo; Villarroel Silva, Pablo Andrés
    Objectives: Laryngeal dystonia (LD) is characterized by irregular and involuntary task-specific spasms of the intrinsic laryngeal muscles. There is no curative treatment for it, however, laryngeal botulinum neurotoxin injections (BoNT-I) are considered th
  • Thumbnail Image
    Item
    Intervenciones breves para promover cambios conductuales en el ámbito de la atención primaria: revisión de su efectividad en consumo de tabaco, alcohol y sedentarismo
    (2018) Rosenbaum Fuentes, Andrés Ricardo; Rojas González, Pamela; Rodríguez, M. V.; Barticevic, N.; Rivera Mercado, Solange
  • Thumbnail Image
    Item
    Role of Prolonged Intubation in Vocal Fold Motion Impairment in Critically Ill Patients
    (2024) Cabrera López, José María; Lagos Villaseca, Antonia Elisa; Fuentes López, Eduardo; Rosenbaum Fuentes, Andrés Ricardo; Willson Easton, Matías Iñigo; Palma Rojas, Soledad De Los Ángeles; Kattan Tala, Eduardo José; Vera Alarcón, María Magdalena; Aquevedo Salazar, Andrés Fernando; Napolitano Valenzuela, Carla Andrea; Cabello Estay, Pablo Andrés
    Summary: Objective. COVID-19 upsurge in orotracheal intubation (OTI) has opened a new opportunity for studying associated complications. Vocal fold motion impairment (VFMI) is a known complication of OTI. The present study sought to determine the impact of OTI and prolonged OTI on the risk of developing VFMI; to identify both risk and protective factors associated with it. Study design. Retrospective cohort study. Setting. Multicenter. Methods. Medical charts were reviewed for all patients that received invasive mechanical ventilation with a subsequent flexible laryngoscopic assessment between March 2020 and March 2022. The main outcomes were the presence of VFMI, including immobility (VFI) and hypomobility (VFH). Results. A total of 155 patients were included, 119 (76.8%) COVID-19 and 36 (23.2%) non-COVID-19 patients; overall 82 (52.9%) were diagnosed with VFMI. Eighty (52.3%) patients underwent a tracheostomy. The median (IQR) intubation duration was 18 (11–24.25) days, while the median (IQR) time to tracheostomy was 22 (16–29). In the adjusted model, we observed there was a 68% increased risk for VFMI from day 21 of intubation (RR: 1.68; 95% CI 1.07–2.65; P = 0.025). Conclusions. VFMI is a frequent complication in severely ill patients that undergo intubation. A prolonged OTI was associated with an increased risk of VFMI, highlighting the importance of timely tracheostomy. Further research is needed to confirm these findings in other subsets of critically ill patients.
  • Thumbnail Image
    Item
    Vacuna contra el virus papiloma humano como tratamiento para la papilomatosis respiratoria recurrente
    (2018) Rosenbaum Fuentes, Andrés Ricardo; Lagos Villaseca, Antonia Elisa; Napolitano Valenzuela, Carla Andrea; Badía Venti, Pedro Ignacio
    Una de las manifestaciones clínicas del virus papiloma humano (VPH) es la papilomatosis respiratoria recurrente (PRR), que se caracteriza por la proliferación de lesiones epiteliales verrucosas recurrentes en la mucosa respiratoria, pudiendo progresar a obstrucción de vía aérea o presentar transformación maligna. El tratamiento de primera línea quirúrgico, pero dada su alta recurrencia ha tomado peso el tratamiento adyuvante, como la vacuna tetravalente contra VPH. Sin embargo, existe controversia respecto a su eficacia. El objetivo de esta revisión es analizar la efectividad de la vacuna contra VPH como tratamiento adyuvante de la PRR, para lo cual hicimos una revisión de la literatura sobre la efectividad de la vacuna tetravalente contra VPH para PRR, realizando una búsqueda en diversas fuentes: Pubmed, MEDLINE, EMBASE, Cochrane, Google Scholar y Epistemonikos. Se seleccionaron los estudios que responden a la pregunta y se analizaron los datos de los estudios primarios. Se encontraron cinco estudios primarios no aleatorizados, todos a favor de la vacuna como tratamiento. Concluimos con baja certeza de evidencia, que la vacuna es posiblemente efectiva para pacientes con PRR en disminuir el número de recurrencias, aumentar el intervalo entre cirugías, lograr remisión completa o parcial de la enfermedad y aumentar significativamente los títulos de anticuerpos anti-VPH